Sarah R Senum

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5024097/publications.pdf

Version: 2024-02-01

759233 752698 20 753 12 20 h-index citations g-index papers 20 20 20 673 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype. American Journal of Human Genetics, 2022, 109, 136-156.	6.2	62
2	Congenital Heart Disease in Adults with Autosomal Dominant Polycystic Kidney Disease. American Journal of Nephrology, 2022, 53, 316-324.	3.1	7
3	Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease. Kidney360, 2022, 3, 465-476.	2.1	2
4	Cardiovascular Outcomes in Kidney Transplant Recipients With ADPKD. Kidney International Reports, 2022, 7, 1991-2005.	0.8	2
5	The genetic landscape of polycystic kidney disease in Ireland. European Journal of Human Genetics, 2021, 29, 827-838.	2.8	11
6	Characteristics of Patients with End-Stage Kidney Disease in ADPKD. Kidney International Reports, 2021, 6, 755-767.	0.8	10
7	Genomics Integration Into Nephrology Practice. Kidney Medicine, 2021, 3, 785-798.	2.0	13
8	Comprehensive Genetic Analysis Reveals Complexity of Monogenic Urinary Stone Disease. Kidney International Reports, 2021, 6, 2862-2884.	0.8	15
9	Genomic diagnostics in polycystic kidney disease: an assessment of real-world use of whole-genome sequencing. European Journal of Human Genetics, 2021, 29, 760-770.	2.8	20
10	Detection and characterization of mosaicism in autosomal dominant polycystic kidney disease. Kidney International, 2020, 97, 370-382.	5.2	44
11	Epidemiology of Autosomal Dominant Polycystic Kidney Disease in Olmsted County. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 69-79.	4.5	39
12	Clinical spectrum, prognosis and estimated prevalence of DNAJB11-kidney disease. Kidney International, 2020, 98, 476-487.	5.2	38
13	The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD. JCI Insight, 2020, 5, .	5.0	41
14	Bacterial Cholangitis in Autosomal Dominant Polycystic Kidney and Liver Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2019, 3, 149-159.	2.4	4
15	The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations. American Journal of Kidney Diseases, 2018, 72, 302-308.	1.9	29
16	Monoallelic Mutations to DNAJB11 Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. American Journal of Human Genetics, 2018, 102, 832-844.	6.2	208
17	Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial. Nephrology Dialysis Transplantation, 2018, 33, 645-652.	0.7	31
18	Long-Term Administration of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1153-1161.	4.5	60

#	Article	IF	CITATIONS
19	Autosomal Dominant Polycystic Kidney Patients May Be Predisposed to Various Cardiomyopathies. Kidney International Reports, 2017, 2, 913-923.	0.8	42
20	Polycystic Kidney Disease without an Apparent Family History. Journal of the American Society of Nephrology: JASN, 2017, 28, 2768-2776.	6.1	75